Table 3

Expression of metastasis-related genes in stage I human NSCLC

Clinicopathological variablesE-cadherinMMP-2MMP-9RationIL-8VEGFbFGF
All cases76.0 ± 34.1124.0 ± 50.2127.0 ± 52.61.88 ± 0.9348151.1 ± 101.1163.0 ± 101.3167.4 ± 102.2
Stage
T1 (n = 27)82.0 ± 42.2129.6 ± 52.4141.0 ± 58.51.94 ± 0.7422181.3 ± 115.0a177.0 ± 116.0178.4 ± 95.0
T2 (n = 33)71.1 ± 25.4119.3 ± 48.5115.6 ± 45.11.83 ± 1.0726124.4 ± 79.4151.2 ± 87.5158.1 ± 108.9
Pathology
Ad (n = 30)69.8 ± 35.5a128.9 ± 60.0134.9 ± 57.42.20 ± 1.1a24182.1 ± 129.9174.4 ± 123.1164.3 ± 101.6
Sq (n = 30)82.2 ± 32.0119.0 ± 38.2119.2 ± 47.11.55 ± 0.3824118.8 ± 39.8115.1 ± 74.4170.5 ± 104.9
Sex
M (n = 42)73.5 ± 29.0125.7 ± 51.6126.5 ± 50.01.95 ± 0.7134132.7 ± 73.2149.9 ± 82.9178.0 ± 113.5
F (n = 18)81.9 ± 44.3120.1 ± 47.9128.3 ± 59.91.84 ± 1.0214192.7 ± 140.4194.9 ± 134.4141.6 ± 63.9
Age
<60 (n = 19)65.6 ± 16.7130.6 ± 50.6126.6 ± 63.31.97 ± 0.7114191.9 ± 134.9191.0 ± 105.5218.3 ± 137.8
≥60 (n = 41)80.8 ± 38.9120.9 ± 50.3127.2 ± 47.81.84 ± 1.0234133.1 ± 77.7151.5 ± 98.746.4 ± 76.5
  • a P < 0.05 by Wilcoxon rank sum.